Nuveen Asset Management LLC Sells 41,918 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Nuveen Asset Management LLC trimmed its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 27.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,716 shares of the company's stock after selling 41,918 shares during the period. Nuveen Asset Management LLC owned approximately 0.15% of CG Oncology worth $3,204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CGON. NEOS Investment Management LLC raised its position in shares of CG Oncology by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after purchasing an additional 817 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in CG Oncology by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company's stock valued at $862,000 after purchasing an additional 1,026 shares in the last quarter. Rhumbline Advisers lifted its position in shares of CG Oncology by 2.2% in the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock valued at $1,979,000 after buying an additional 1,458 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of CG Oncology by 16.4% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,834 shares of the company's stock valued at $368,000 after buying an additional 1,810 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of CG Oncology by 7.0% in the fourth quarter. MetLife Investment Management LLC now owns 29,026 shares of the company's stock valued at $832,000 after buying an additional 1,894 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CGON. Morgan Stanley dropped their price target on CG Oncology from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Monday, May 19th. JPMorgan Chase & Co. began coverage on CG Oncology in a report on Friday, May 2nd. They set an "overweight" rating and a $41.00 price target for the company. Scotiabank began coverage on CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $58.22.

CG Oncology Trading Up 0.2%

NASDAQ CGON traded up $0.05 during midday trading on Thursday, hitting $26.63. The company had a trading volume of 1,163,732 shares, compared to its average volume of 826,735. The company has a market capitalization of $2.03 billion, a PE ratio of -17.64 and a beta of 0.86. The firm has a 50-day moving average price of $23.09 and a 200-day moving average price of $27.15. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.09). The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.53 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. On average, equities analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current year.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total value of $30,760.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.40% of the company's stock.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.